Sinopharm Group and Pfizer formalized a strategic partnership at Sinopharm's
headquarters. The agreement focuses on iterative market promotion of Diflucan
(fluconazole) formulations—fluconazole injection and capsules—and on cooperation
to upgrade services for Pfizer's future product launches in China.